Background: The antifungal armamentarium includes a number of drug classes and agents
within each class. Successful IFI management depends on optimal matching of drug choice …

ABSTRACT Introduction: Invasive fungal infections (IFIs) remain a significant cause of
morbidity and mortality despite significant advancements in currently available therapy. With …

Antifungal pharmacodynamics can be used to understand the relationship between drug
dosing, in-vitro susceptibility and treatment efficacy. Consideration of these relationships can …

Introduction: Invasive fungal infection carries a high morbidity, mortality and economic cost.
In recent times, a rising incidence of fungal infection and antifungal resistance is occurring …

Traditionally, many invasive fungal infections were associated with a poor prognosis,
because effective therapeutic options were limited. The recent development of new …

Over the past several years, the incidence of invasive fungal infections has dramatically
increased. 1, 2 In fact, Candida species (spp) are the fourth most common cause of …

The prevalence of invasive fungal infections (IFIs) has increased over the past three
decades owing to the increasing numbers of immunocompromised hosts. These infections …

Over the past 15 years, there has been an increase in development and utilization of newer
antifungal agents. The ideal antifungal agent in regard to spectrum of activity …

Invasive fungal infections remain a major cause of morbidity and mortality in
immunocompromised patients, and such infections are a substantial burden to healthcare …

Early treatment of invasive fungal infections (IFIs) is essential for optimal clinical outcomes.
Standard antifungal drugs (polyenes, azoles and echinocandins) are not predictably …